Eye Injuries Clinical Trial
Official title:
An Exploratory Study of Visual Function Rehabilitation in Patients With Ocular Trauma
Ocular trauma is one of the leading causes of blindness worldwide, often resulting in severe visual impairment or even loss of vision after injury. Although after powerful surgical treatment, there are still some patients whose visual function is difficult to improve, and the patients with eye trauma lack effective vision rehabilitation therapy.Therefore, the research on visual function rehabilitation of patients with ocular trauma needs to be further carried out . Perceptual learning is based on cortical remodeling, repetitive visual task training. This training is to perform a series of repetitive visual tasks through the Gabor patch, simulating the receptive field structure of simple cells in the primary visual cortex (V1 area), "awakening visual cells", and improving the visual processing ability of the cerebral cortex. Compared with the traditional vision rehabilitation therapy, perceptual learning optimizes the visual quality at the visual center level. It is an innovative therapy, having the potential to solve the visual function of patients with eye trauma. This study intends to explore new visual rehabilitation methods for patients with ocular trauma, and explore the changes in visual cortical function and area of patients after perceptual training.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Retinopathy, optic neuropathy, endophthalmitis and other injuries caused by ocular trauma, with varying degrees of central vision reduction and visual field impairment 2. Age 3~60 years old 3. Best corrected visual acuity of the affected eye: 20/200=BCVA=20/25 4. Intraocular pressure is normal, non-hypotonal/atrophic: 7--21mmHg 5. After the traumatic injury, the condition is stable =for 3 months after treatment, and the visual axis has a complete and transparent optical pathway 6. If the patient is injured in one eye, There were no abnormal lesions in the contralateral eye, no abnormalities in slit lamp and indirect ophthalmoscopy, and no peripheral retinopathy in both eyes was found on triprimmoscopy. Carefully ask for a history of no other eye disease in both eyes and a systemic history that has caused an associated eye disease or has affected visual formation. 7. The cranial structure is intact, the function is good, and there is no primary or secondary injury 8. Able to cooperate with the questionnaire and treatment, good compliance 9. Those who are willing to sign the informed consent form Exclusion Criteria: 1. Have active inflammation of the eye 2. Previous abnormal intraocular blood supply such as occlusion of the central intraocular artery due to trauma or non-traumatic factors 3. History of other non-traumatic intraocular surgery 4. Ocular related lesions caused by other non-traumatic factors that can interfere with this study, such as age-related macular degeneration, glaucoma, amblyopia, etc. 5. Use of other rehabilitation training methods or visual aids 3 months before enrollment 6. Lesions with systemic diseases whose degree of lesions have affected visual function, such as diabetic retinopathy, Hypertension and arteriosclerotic fundus changes, rubella-related ocular changes, etc. 7. Patients with severe systemic diseases such as renal failure and malignant hypertension or may affect visual function (such as retinal structure and function, choroidal structure and function, etc.) 8. Patients with congenital ocular lesions 9. Patients with optic nerve and retinopathy caused by non-traumatic factors 10. Patients with cranial brain disease or craniocere-related lesions with poor cortical function 11. Psychological related diseases 12. MRI contraindications, Such as claustrophobia and non-MRI compatible metal implants 13. people with speech impairment and intellectual disability 14. those who are considered inappropriate by the investigator |
Country | Name | City | State |
---|---|---|---|
China | Zhonshan Ophthalmic Center, Sun Yat-Sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhongshan Ophthalmic Center, Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Best Corrected Visual Acuity | Log MAR | 3 months | |
Secondary | Contrast Sensitivity Function | Area Under the Log Contrast Sensitivity Function | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04521283 -
Visual Outcome of Traumatic Posterior Segment Complications
|
||
Not yet recruiting |
NCT03908515 -
Multi-center Clinical Observation of FCVB in Guangdong Province
|
||
Completed |
NCT05771467 -
Evaluation of Retinal Microvascular Change That May Develop in Patients After Open Globe İnjury With Optical Coherence Tomography (OCTA)
|
||
Completed |
NCT00129077 -
Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?
|
N/A | |
Completed |
NCT01490593 -
Canadian Eye Injury Registry
|
N/A | |
Recruiting |
NCT03706560 -
Professional Consequences of Ocular Trauma Hospitalized at the Hospital Centre of Clermont-Ferrand
|
||
Not yet recruiting |
NCT05164588 -
A Prospective Study of Traumatic Eye Injuries in the Period From January 2022 to June 2022 in Sohag University Hospitals
|
||
Completed |
NCT02638025 -
Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury
|
N/A | |
Completed |
NCT04595357 -
"Iris Shelf" Technique for Intraocular Foreign Bodies Removal
|
||
Completed |
NCT04837534 -
Improving the Follow up Rate for Pediatric Patients
|
N/A | |
Completed |
NCT00598299 -
Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Auto-Serum and Cord Blood Serum
|
N/A | |
Terminated |
NCT00211367 -
Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
|
Phase 2 |